Mark A. Socinski, MD

Mark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.

Mark A. Socinski, MD, discusses how the FLAURA trial led to the adoption of osimertinib for patients with non–small cell lung cancer and EGFR mutations.

Mark A. Socinski, MD, discusses types of EGFR mutations in non–small cell lung cancer and the treatments that target these mutations.

In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.

Dr Mark Socinski reviews the challenges faced when treating chemotherapy induced myelosuppression and discusses the impact of trilaciclib on CIM and how that will impact clinical practice.

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.

Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.

Mark A. Socinski, MD, professor, Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, University of Pittsburgh, discusses the adverse events, as well as the overall significance, of nivolumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC).